Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.25 USD | -0.65% | -0.97% | -39.09% |
Apr. 30 | Neogen® Launches New Molecular Method for Detection of Two Salmonella Serotypes | CI |
Apr. 18 | Neogen Corporation Forms Genomics Relationship with Performance Food Group | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.09% | 2.65B | C | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.52B | A | ||
+1.43% | 50.06B | B- | ||
+11.60% | 45.67B | B- | ||
+3.40% | 41B | B+ | ||
+3.03% | 26.73B | B | ||
+3.21% | 26.47B | A- | ||
+15.23% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEOG Stock
- Ratings Neogen Corporation